SCHEMBL6964481

SCHEMBL6964481

CC(C)c1ccccc1Sc1c(O)cc(-c2cccc(O)c2)oc1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.44
PARP1 P09874 2/20 0.44
TNKS2 Q9H2K2 2/20 0.44
CYP3A4 P08684 4/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
CYP2C9 P11712 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
POLH Q9Y253 1/20 0.40
TP53 P04637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TERT O14746 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961039 0.90 SMN1; SMN2 (0.46) TNKSPARP1TNKS2CYP3A4MAPT
SCHEMBL6961237 0.90 QPCT (0.42) TNKSPARP1TNKS2CYP3A4MAPT
SCHEMBL6963792 0.89 GABRP (0.43) TNKSPARP1TNKS2MAPTKMT2A
SCHEMBL6963494 0.88 PTGES (0.43) TNKSPARP1TNKS2CYP3A4MAPT
SCHEMBL6958727 0.86 CYP1A2 (0.42) MAPTALDH1A1MEN1KMT2ATP53
SCHEMBL6959051 0.85 ABCB1 (0.43) TNKSPARP1TNKS2CYP3A4MAPT
SCHEMBL6960294 0.85 QPCT (0.39) TNKSPARP1TNKS2MAPTALDH1A1
SCHEMBL6959292 0.85 POLB (0.35) TNKSPARP1TNKS2CYP3A4MAPT
SCHEMBL6964073 0.85 AR (0.41) TNKSPARP1TNKS2MAPTALDH1A1
SCHEMBL6965601 0.84 NPSR1 (0.42) TNKSPARP1TNKS2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed